ArticleDigestive diseases and sciences2025
Unraveling the Role of Leukotriene A4 Hydrolase in Hepatocellular Carcinoma: Implications for Targeted Therapy and Tumor Progression.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLiver cancer represents a significant health burden, with hepatocellular carcinoma (HCC) accounting for most cases. Despite treatment advances, HCC prognosis remains poor, underscoring the need for a deeper understanding of its molecular mechanisms.
aimThis study explores the role of leukotriene A4 hydrolase (LTA4H) and its product, leukotriene B4 (LTB4), in HCC progression.
methodsBioinformatic analysis was used to evaluate the expression profiles of LTA4H and LTB4 receptors, LTB4R and LTB4R2, in human HCC samples. 2D and 3D cultures of HCC cells were treated with the selective LTA4H inhibitor SC-57461A to assess cell viability, proliferation, migration, invasion, and apoptosis. In vivo studies in nude mice bearing human HCC xenografts treated with SC-57461A were performed to evaluate tumor growth and proliferation markers (PCNA and Ki-67).
resultsGene expression analysis revealed significant upregulation of LTA4H and its receptors in HCC tissues compared to healthy liver samples. 2D and 3D cultures of human HCC cells treated with SC-57461A showed reduced cell viability, migration, invasion, and proliferation and apoptosis. In mice orthotopically implanted with human HCC cells and treated with SC-57461A, tumor growth rate, size, and proliferation marker levels were markedly decreased.
conclusionsThis study identifies LTA4H as a critical factor in HCC, suggesting its potential as a prognostic biomarker. The findings also highlight the promise of LTA4H inhibitors as a new approach for developing more effective treatments for liver cancer.
Indexed as
Identifiers
40580380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.